Intravenous immunoglobulin 2697827 224541220 2008-07-09T09:20:04Z 212.117.142.227 /* Complications and side effects */ '''Intravenous immunoglobulin''' (IVIG) is a [[Blood donation|blood product]] administered [[intravenous]]ly. It contains the pooled [[IgG]] [[immunoglobulins]] ([[antibodies]] extracted from the [[Blood plasma|plasma]] of over a thousand blood donors). IVIG's effects last between 2 weeks and 3 months. It is mainly used as treatment in three major categories: * [[Immune deficiency|Immune deficiencies]] - Immune deficiencies such as [[X-linked agammaglobulinemia]], [[hypogammaglobulinemia]] (primary immune deficiencies), and acquired compromised immunity conditions ([secondary immune deficiencies), featuring low [[antibody]] levels. * [[inflammation|Inflammatory]] and [[autoimmunity|autoimmune diseases]]. * Acute infections. == Mechanism of action == IVIG is given as a plasma protein replacement therapy (IgG) for immune deficient patients which have decreased or abolished [[antibody]] production capabilities. In these immune deficient patients, IVIG is administered to maintain adequate [[antibodies]] levels to prevent [[infection]]s and confers a passive immunity. Treatment is given every 3-4 weeks. In the case of patients with autoimmune disease, IVIG is administered at a high dose (generally 1-2 grams IVIG per kg body weight) to attempt to decrease the severity of the autoimmune disease. The precise mechanism by which IVIG suppresses harmful [[inflammation]] has not been definitively established but is believed to involve the inhibitory [[Fc receptor]].<ref>[http://pediatrics.aappublications.org/cgi/content/full/110/2/S1/467-b]James E. Gern, MD. "Antiinflammatory Activity of IVIG Mediated through the Inhibitory FC Receptor" PEDIATRICS Vol. 110 No. 2 August 2002, pp. 467-468</ref><ref>[http://www.jem.org/cgi/content/abstract/204/1/11] Falk Nimmerjahn and Jeffrey V. Ravetch. "The antiinflammatory activity of IgG: the intravenous IgG paradox". The Journal of Experimental Medicine, Vol. 204, No. 1, 11-15</ref> The actual primary target(s) of IVIG in autoimmune disease are still unclear, however. IVIG may work via a multi-step model where the injected IVIG first forms a type of immune complex in the patient. <ref>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=539209 Raphael Clynes Immune complexes as therapy for autoimmunity. J Clin Invest. 2005 January 3; 115(1): 25–27. doi: 10.1172/JCI200523994. PMID: 15630438</ref> Once these immune complexes are formed, they interact with activating Fc receptors on dendritic cells<ref>http://www.ncbi.nlm.nih.gov/pubmed/16715090 Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med. 2006 Jun;12(6):688-92. PMID: 16715090</ref>which then mediate anti-inflammatory effects helping to reduce the severity of the autoimmune disease or inflammatory state. Additionally, the donor antibody may bind directly with the abnormal host antibody, stimulating its removal. Alternatively, the massive quantity of [[antibody]] may stimulate the host's [[complement system]], leading to enhanced removal of all antibodies, including the harmful ones. IVIG also blocks the antibody receptors on immune cells ([[macrophage]]s), leading to decreased damage by these cells, or regulation of macrophage [[phagocytosis]]. IVIG may also regulate the immune response by reacting with a number of membrane receptors on [[T cells]], [[B cells]], and [[monocytes]] that are pertinent to autoreactivity and induction of tolerance to self.<ref>Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, Bellon B, Kaveri S, Kazatchkine MD. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003; 24: S217–S221.</ref> A recent report stated that IVIG application to activated [[T cells]] leads to their decreased ability to engage [[microglia]]. As a result of IVIG treatment of T cells, the findings showed reduced levels of [[tumor necrosis factor-alpha]] and [[interleukin-10]] in T cell-microglia co-culture. The results add to the understanding of how IVIG may affect inflammation of the central nervous system in [[autoimmunity|autoimmune]] inflammatory diseases.<ref>Janke AD, Yong VW. Impact of IVIG on the interaction between activated T cells and microglia. Neurol Res. 2006 Apr;28(3):270-4. PMID 16687052</ref> IVIG is useful in some acute infection cases such as in [[Kawasaki's Disease]] and [[pediatric]] [[HIV]] infection. == IVIG notes == * IVIG is an infusion of [[Immunoglobulin G|IgG]] [[antibody|antibodies]] only. Therefore, peripheral tissues that are defended mainly by [[IgA]] antibodies, such as the [[eye]]s, [[lung]]s, [[gastrointestinal tract|gut]] and [[urinary tract]] are not fully protected by the IVIG treatment. * [[x-linked agammaglobulinemia|XLA]] patients are immune to the most virulent adverse effect, [[anaphylaxis|anaphylactic shock]], as they do not have the antibodies to react against the treatment. Anaphylactic shock has a higher chance to occur in [[Immunoglobulin A|IgA]] deficient patients which do have other antibody types. * In case of recurring side effects, it is recommended to slow the pace of the IVIG administration and to reduce the dosage. It is also advisable to change IVIG brand, as some people react against to a specific brand. * If the patient is [[diabetes|diabetic]], he should take into consideration the medium in which the antibodies are solubilized in the IVIG treatment, as some brand solubilize antibodies with high concentrated [[sugar]]s (such as [[sucrose]] and [[maltose]]). * [[FDA]] guidelines for IVIG state the product should be: ** Prepared out of at least 1,000 different human donors. ** All four IgG subgroups (1-4) should be present. ** The IgG should maintain biological activity and lifetime of at least 21 days. ** Does not contain samples which are [[HIV]], [[hepatitis B]], [[hepatitis C]] positive. ** Screened and treated in a manner that destroys [[virus]]es. * IVIG is also considered a modulator of the [[immune system]] and was shown to be beneficial in treating numerous [[autoimmune]] diseases such as relapsing and remitting [[multiple sclerosis]] (MS), [[myasthenia gravis]], [[pemphigus]], [[polymyositis]] (PM), [[dermatomyositis]] (DM), [[Wegener's granulomatosis]] (WG), [[Churg-Strauss syndrome]], [[chronic inflammatory demyelinating polyneuropathy]] (CIDP) and more. * IVIG can be given to pregnant women. * IVIG is also used as a treatment for unexplained recurring miscarriages. The effectiveness of the therapy is controversial. *IVIG cost is climbing and well over $50/g. ($10,000 for a 220lbs person at 2g/kg) == Uses of IVIG == Dosage of IVIG is dependent on indication. For primary immune dysfunction 100 to 400 mg/kg of body weight every 3 to 4 weeks is implemented. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three to six months over a five day course once a month. Then maintenance therapy of 100 to 400 mg/kg of body weight every 3 to 4 weeks follows. === FDA-approved indications === * [[Hematopoietic stem cell transplantation|Allogeneic bone marrow transplant]] * [[Chronic lymphocytic leukemia]] * [[Idiopathic thrombocytopenic purpura]] * [[Pediatric HIV]] * Primary immunodeficiencies * [[Kawasaki disease]] * [[Kidney transplant]] with a high antibody recipient or with an ABO incompatible donor * Common Variable Immune Deficiency In 2004 the FDA approved the Cedars-Sinai IVIG Protocol which has been 90-95% successful in removing antibodies from the blood of kidney transplant recipients so that they can accept a living donor kidney from any healthy donor no matter blood type (ABO incompatible) or tissue match. === Off-label Uses === * [[Chronic fatigue syndrome]] * [[Chronic inflammatory demyelinating polyneuropathy]] (CIDP) * [[Clostridium difficile]] colitis * [[Dermatomyositis]] and [[polymyositis]] * [[Graves disease|Graves' ophthalmopathy]] * [[Guillain-Barré syndrome]] * [[Kawasaki disease]] * [[Muscular Dystrophy]] * [[Inclusion body myositis]] * [[Lambert-Eaton myasthenic syndrome|Lambert-Eaton syndrome]] * [[Lupus erythematosus]] * [[Multifocal motor neuropathy]] * [[Multiple sclerosis]] * [[Myasthenia gravis]] * [[Neonatal alloimmune thrombocytopenia]] * Parvovirus B19 * [[Pemphigus]] * [[Post-transfusion purpura]] * [[Renal transplant rejection]] * [[Spontaneous Abortion/Miscarriage]] * [[Stiff person syndrome]] * Severe sepsis and [[septic shock]] in critically ill adults<ref name="CritCare">Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. ''Crit Care Med''. 2007;35(12):2686-92. PMID 18074465</ref> * [[Toxic epidermal necrolysis]] * In [[chronic lymphocytic leukemia]] and [[multiple myeloma]], as well as various rare deficiencies of immunoglobulin synthesis (e.g. [[X-linked agammaglobulinemia]], [[hypogammaglobulinemia]]), IVIG is administered to maintain adequate immunoglobulin levels to prevent [[infection]]s. == Complications and side effects == Complications of IVIG therapy include * [[headache]] * [[dermatitis]] - usually peeling of the skin of the palms and soles * infection (such as [[HIV]] or [[viral hepatitis]]) by contaminated blood product; there is also an as yet unknown risk of contracting [[variant CJD]] ([[Creutzfeldt-Jakob disease|vCJD]]). * [[pulmonary edema]] from fluid overload, due to the high [[oncotic pressure|colloid oncotic pressure]] of IVIG * [[allergy|allergic]]/[[anaphylaxis|anaphylactic]] reactions * damage such as [[hepatitis]] caused directly by antibodies contained in the pooled IVIG * [[acute renal failure]] * [[venous thrombosis]] * [[aseptic meningitis]] ==References== {{reflist}} [[Category:Glycoproteins]] [[Category:Antibodies]] [[Category:Immune system]] [[Category:Medical treatments]] 5. Noah S Scheinfeld. Intravenous Immunoglobulin. Emedicine. http://www.emedicine.com/med/topic3546.htm [[he:נוגדן תוך ורידי]]